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ABSTRACT 
 
LMEA, A CONSERVED CELL-ENVELOPE PROTEIN IN MYCOBACTERIA, IS 
IMPORTANT FOR ANTIBIOTIC RESISTANCE AND CELL ENVELOPE 
PERMEABILITY 
 
MAY 2020 
SARAH HASSAN OSMAN 
B.S. UNIVERSITY OF MASSCHUSETTS AMHERST 
M.S. UNIVERSITY OF MASSCHUSETTS AMHERST 
Directed by: Professor Yasu S. Morita 
 
The cell envelope of mycobacteria is critical for the survival and virulence of pathogenic 
species during infection, and its biosynthesis has been a proven drug target. Therefore, finding 
new targets in the biosynthetic pathway of cell envelope components is of great interest. 
Mycobacterium smegmatis is a model organism for the study of the devastating pathogen 
Mycobacterium tuberculosis. Previously, lipomannan elongation factor A (LmeA) has been 
identified as a cell envelope protein that is critical for the control of mannan chain length of 
lipomannan (LM) and lipoarabinomannan (LAM), lipoglycan components of the cell envelope. 
The deletion mutant, ∆lmeA, accumulates abnormal LM/LAM with fewer mannan residues. To 
understand the importance of this protein, the antibiotic sensitivity of ∆lmeA was tested using a 
 vi 
resazurin-based viability assay. We found that the lmeA deletion leads to increased sensitivities 
to antibiotics such as vancomycin and erythromycin, and lmeA overexpression leads to increased 
antibiotic resistance. To directly test if the increased antibiotic sensitivity is due to the defective 
permeability barrier, we used an ethidium bromide uptake assay and found that ∆lmeA is more 
efficient in taking up ethidium bromide in the cell. We have also found that LmeA is important 
for protein stabilization under stress conditions. MptA is an α1,6-mannosyltransferase involved 
in elongation of LM and LAM mannan chain. During stress conditions in the ΔlmeA mutant, 
levels of MptA decrease significantly relative to wild-type. This also results in delayed doubling 
time after stress, a phenotype not seen in this mutant under normal growth conditions. In 
addition, the ΔlmeA mutant has differential protein expression during stress conditions relative to 
ΔlmeA in log phase, or to wild-type in either condition. To help elucidate the role of LmeA at the 
molecular level, binding behavior of this protein to membrane fractions was determined. In a 
subcellular fractionation analysis, LmeA localizes to fractions containing plasma membrane, 
which is tightly bound to cell wall layers. To test the binding of LmeA to membrane further, 
LmeA was heterologously expressed in Escherichia coli, purified, and mixed M. smegmatis cell 
lysate. LmeA localized to intracellular domain fractions (IMD), indicating that LmeA is capable 
of localizing to fractions containing only plasma membrane. Consistent with this finding, LmeA 
is capable of binding to spheroplasts in both an ELISA setting as well as in a sucrose gradient 
fractionation setting. It has also been determined that ΔlmeA has a defective capsular layer with a 
unique phenotype relative to other strains. We have concluded that LmeA is important for 
antibiotic resistance, cell envelope permeability, capsule formation, stress response, and have 
also determined its binding properties.  
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Chapter 1 
Introduction 
 
1.1 Medical relevance  
 
Mycobacteria are a medically relevant genus of bacteria. In particular, Mycobacterium 
tuberculosis (M. tb), the human pathogen and main causative agent of tuberculosis, is of global 
concern. M. tb has played a large role throughout history, wiping out large portions of societies 
and shaping disease surveillance. The earliest evidence of M. tb infections has been found in 
human remains going back as far as 5000 BCE in Peru and Egypt 1. The earliest documents 
found describing tuberculosis date back 3,300 years ago in India2. Later, between the 1600s and 
1800s, tuberculosis accounted for one quarter of all deaths in Europe3. Although there have been 
great public health and medical advances, tuberculosis is a health issue countries continue to 
battle globally. It is estimated that about one-quarter of the current global population is infected 
with M. tb4 . Of this group, between 5 and 15 percent will go on to develop active tuberculosis 
with the remaining percentage having dormant, non-infectious, and non-disease-causing M. tb 
infections5 . These numbers translate into 10 million new, active cases each year and 1.5 million 
deaths4 . The majority active M. tb infections occur in low- and middle-income countries, but the 
disease is still widespread. For example, in the United States, 8,920 cases of active tuberculosis 
were reported, with an estimated 13 million latent infections5 . The treatment of tuberculosis is 
multi-pronged and lengthy, requiring the use of many drugs over a long period of time. Standard 
treatment for non-drug resistance tuberculosis in non-HIV patients consists of a two-month 
intensive phase of isoniazid, rifampin, pyrazinamide, and ethambutol followed by a four-month 
phase of isoniazid and rifampicin6. Despite the global research effort and the many 
advancements in understanding this pathogen, the discovery of new drugs for tuberculosis 
treatment has stalled, with only one new drug meeting FDA approval in the past 40 years7. This 
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is especially concerning due to the rise in multidrug-resistance and extensively drug-resistant 
tuberculosis infections8.   
 
1.2 Cell Envelope Overview 
 A large part of what makes M. tb such a good pathogen is its complex and waxy cell 
envelope. This multilayered barrier protects the cell from threats like antibiotics and host 
defenses and can even modulate the human immune system9. In addition to providing protection 
to the cell, the cell envelope is necessary to provide the rigidity and shape to these rod-shaped 
microbes. The mycobacterial cell envelope is composed of several layers. The innermost layer 
begins with the plasma membrane, a phospholipid bilayer. This plasma membrane is composed 
of different lipids such as cardiolipin, phosphatidylethanolamine, phosphatidylinositol, 
phosphatidylinositol mannosides (PIMs), and menaquinones, as well as others. Furthermore, 
mycobacterial compartmentalize plasma membrane. In Mycobacterium smegmatis, the non-
pathogenic and fast-growing model organism for M. tb, a lipid domain coined intracellular 
membrane domain (IMD) is spatially distinct from the rest of the plasma membrane10. The IMD 
contains unique metabolic enzymes often involved in cell envelope biosynthesis, and these 
proteins tend to localize to the polar regions of the cell. The IMD is also dynamic, responding to 
environmental stresses such as starvation11.  The next layer is a thick peptidoglycan core, on par 
with other gram-positive bacteria, with the periplasmic space residing underneath. This mesh of 
sugars and amino acids allows the cell to maintain its shape and rigidity12 . When this 
peptidoglycan layer is removed and digested by lysozyme, the cell changes shape and eventually 
lyses. Moving upwards is the arabinogalactan layer. This layer is composed of galactose and 
arabinose polymers and is covalently bound to the outer membrane above it, also known as the 
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mycomembrane. The outer membrane is heavy in mycolic acids and abundant in glycans and 
lipids like lipomannan and lipoarabinomannan, glycolipids with great significance in immune 
modulations13. This membrane forms a sort of bilayer lipidic membrane, similar in structure to 
the plasma membrane. Current research suggests that the inner leaflet of this layer is mostly 
formed of mycolic acids while the outer leaflet of different lipidic species like trehalolipids and 
possibly lipomannan and lipoarabinomannan14. These mycolic acids covalently link this layer to 
the arabinogalactan layer. Finally, there is the capsule, the outermost layer made of 
polysaccharides that directly interacts with the environment surrounding the microbe. The 
capsular layer plays a role in variety of processes such as the formation of biofilms and host 
immunity resistance15. This layer is non-covalently attached and can be visualized by electron 
microscopy. The mycobacterial capsule is composed of uncharged polysaccharides such as α-
glucan, arabinomannan, and mannan. The capsule can be visualized by the mannan and glucan 
binding fluorescent-conjugated lectin, Concanavalin A. The capsule plays a role in host immune 
response, with host receptors recognizing α-glucan16 . 
 
 
 
 
 
 
 
 
 4 
 
 
 
Figure 1.1: The Mycobacterial Cell Envelope Figure taken from Pathogens and Disease, Volume 76, 
Issue 4, June 201810. The mycobacterial cell envelope begins with the plasma membrane. The periplasmic 
space sits between the plasma membrane and the peptidoglycan core. Moving upwards, an 
arabinogalactan layer is followed by the outer membrane. The outermost layer is the capsule.  
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1.3 Biosynthesis of Cell Envelope Components 
 The biosynthesis of different components and layers of the mycobacterial cell envelope is 
a complex process involving the use of many different enzymes and other proteins. Of relevance 
to this study is the biosynthesis of phosphatidylinositol mannosides, lipomannan, and 
lipoarabinomannan, major components of the plasma membrane.  
The most abundant PIM species in M. smegmatis, the model organism for M. tb, are 
AcPIM2 and AcPIM6. Production of these PIMs begin with the synthesis of phosphatidylinositol 
(PI) from inositol and cytidine diphosphate diacylglycerol (CDP-DAG). This reaction requires 
no energy input and is controlled by the PI synthase PgsA, which has been found to be essential 
in M. smegmatis 17.  From there, PI can be decorated with varying numbers of mannose residues 
and fatty acid modifications. In the case of AcPIM2, PI has two mannose residues added 
sequentially by PimA and PimB’ respectively18 . An acyl chain is then added to one of the 
mannose residues by PatA19 . The enzymes responsible for the first two mannose additions, 
PimA and PimB’, mostly likely operate on the cytoplasmic side of the plasma membrane, as 
suggested by the fact that they are GDP-mannose-dependent enzymes. The formation of AcPIM6 
is less clear. The mannosyltransferase(s) that form AcPIM4 from AcPIM2 is still unknown in 
mycobacteria. After AcPIM4 is formed, a mannosyltransferase termed PimE drives the 
production of AcPIM6 by adding a fifth mannose to AcPIM4 using polyprenol-phosphate-
mannose (PPM) as a mannose donor20 . 
Lipomannan (LM) and lipoarabinomannan (LAM) biosynthesis begins with AcPIM4. A 
lipoprotein termed LpqW has been shown to be involved in the branching point of AcPIM4 to 
either AcPIM6 or LM/LAM21 . The mannan chain of AcPIM4 is elongated to 5-20 residues to 
form an LM intermediate. MptA, another mannosyltransferase, elongates this α1,6 mannan chain 
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to 21-34 residues22 . The protein of focus in this study, LM elongation factor A (LmeA), is 
necessary for the α1,6 mannan elongation by MptA. The mannosyltransferase MptC decorates 
the α1,6 mannan backbone by α1,2 mono-mannose chains.23  To form LAM, one arabinan 
residue is attached to the mannan backbone. The first arabinosyltransferase is still unknown but 
EmbC, an α1,3 araibonsyltransferase, elongates the primed arabinose24 . AftC and AftB are also 
involved in this arabinan addition as well as arabinogalactan biosynthesis25,26 .  
 
Figure 1.2: Biosynthesis of Phospholipids, PIMs, and LM/LAM. Figure by Kathryn Rahlwes 27.   
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1.4 Intracellular Membrane Domain 
 A lipid domain coined intracellular membrane domain (IMD) has been characterized in 
M. smegmatis17. This is a dynamic but spatially distinct part of the plasma membrane in 
mycobacteria which contains cell envelope biosynthetic reactions. Mycobacteria grow in a polar 
manner, suggesting that there may be spatiotemporal control mechanisms to provide cell 
envelope precursors to this area. Microscopy has shown that IMD proteins tend to localize and 
be enriched in the polar regions of the cell. The IMD, or plasma membrane free of cell wall 
components, is biochemically separate from plasma membrane components that are bound to cell 
wall fractions (PMCW). In a sucrose gradient fractionation, IMD proteins go to unique fractions, 
separate from cytoplasmic and PMCW proteins. Proteomic analysis has shown that these IMD 
fractions enzymes related to the biosynthesis of PIMs, suggesting it plays a major role in PIM 
metabolism. The IMD is dynamic and responsive to environmental stresses11. The IMD localizes 
specifically to the polar region where active growth is taking place. The IMD also repositions 
from the poles to the sidewall during starvation or other stress conditions11 . 
 
1.5 Spheroplasts 
 As previously mentioned, the mycobacterial membrane is complex and multilayered. 
Spheroplasts have the mycomembrane and cell wall layers stripped off. In order to do this, 
glycine is added to inhibit the biosynthesis of peptidoglycan28. Then, lysozyme is added to 
remove any existing peptidoglycan. As the peptidoglycan is removed, all the layers above it are 
also removed. Without this peptidoglycan exoskeleton, the resulting wall-deficient cell 
transitions from a rod to a sphere. Spheroplasts are especially fragile, requiring the use of 
osmotic protective media in order to keep these cells from lysing. Studies have shown that only 
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the lipidic anchors of LM and LAM are left the cell envelope after spheroplasting29 . This form 
of mycobacterial cells can be especially useful in characterizing plasma membrane associated 
proteins.  
 
 1.6 M. smegmatis’s Relevance to M. tuberculosis  
 
 M. tb and M. smegmatis are species of bacteria within the class of actinobacteria. They 
are gram-positive, rod shaped cells that grow by inserting new cell envelope material at the 
poles. A defining feature of these mycobacteria are the high GC content, with M. tb measuring at 
65.6% and M. smegmatis measuring at 67.4% 30. Another defining feature of these species are 
their complex and multilayered cell envelope, of which the two are highly similar. M. smegmatis 
is often used as the model organism to study M. tb and other pathogenic mycobacteria due to its 
non-pathogenicity and fast doubling time. M. smegmatis doubles every 3-4 hours while M. 
tuberculosis doubles every 24 hours. M. smegmatis shares high genome identity with M. 
tuberculosis, making it a good model for study31. This study will use M. smegmatis as a model, 
and all proteins mentioned in the results section have been confirmed to have homologs in M. 
tuberculosis.  
 
 
1.7 Previous Data and Aims of this Study 
 
 The biosynthesis of cell envelope components is a proven target in treating M. 
tuberculosis infections. Ethambutol, one of the few drugs approved to treat tuberculosis, inhibits 
the enzyme that polymerizes arabinose into arabinogalactan32. Isoniazid, another drug used for 
treatment, inhibits the synthesis of mycolic acids33. Therefore, it is reasonable to expect that the 
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next approved drug may target a protein involved in cell envelope biosynthesis, so understanding 
these pathways is of importance.  
 Previously, it has been shown that the deletion of the pimE gene, which encodes the 
enzyme responsible for the committed step in AcPIM6 formation, results in a small colony 
morphology34. This small colony morphology was used to identify suppressor mutants of ∆pimE, 
some of which had significantly shorter LM and LAM. After genome sequencing, it was shown 
that some of these suppressor mutants had a mutation in MSMEG_5785, or lmeA. Subsequent 
testing showed that LmeA is a PMCW protein and ∆lmeA results in short LM and LAM, but not 
a change in colony size or doubling time35 . It was also found that in ∆lmeA under stress 
conditions, MptA degradation occurs (Rahlwes KC, unpublished observations). Lastly, it was 
shown that LmeA binds to phospholipids35. These previous data provide clues to LmeA’s role, 
but its exact function is still unclear. This study further elucidated LmeA’s role in cell envelope 
biosynthesis and includes the following chapters: 
I. Chapter 2: Impact of LmeA on Cell Envelope Integrity and Homeostasis: This 
aim includes antibiotic sensitivity, cell envelope permeability, protein expression 
under log and starvation conditions, and capsule staining. 
II. Chapter 3: LmeA Localization and Cell-Envelope Binding Properties: This aim 
includes LmeA binding in-vivo, in-vitro, and to spheroplasts. 
III. Chapter 4: LmeA’s Role in MptA Stabilization and Possible Interactions with 
ThiX: This chapter includes the characterization of ∆lmeA under stress conditions 
and the investigation of the relevance of ThiX, a protein encoded by a gene in the 
same operon as LmeA.   
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Chapter 2 
Impact of LmeA on Cell Envelope Integrity and Homeostasis 
 
2.1 Previous Data Within This Aim 
 lmeA was first identified by finding suppressor mutants of ∆pimE. pimE encodes the first 
committed step in phosphatidylinositol hexomannoside biosynthesis in M. smegmatis and a 
knockout mutant of this gene results in a small colony morphology. This small colony morphology 
was used to find suppressor mutants that restored the wild-type colony size morphology. Of the 
suppressor mutants that were found, three suppressor mutants termed S1, S10, and S22 had 
mutations in MSMEG_5785. This gene was later termed lmeA. These suppressor mutants were 
able to restore colony size but had smaller LM and LAM. Complementation of lmeA to these 
∆pimE mutants with non-functional LmeA were able to restore LM and LAM back to the WT 
phenotype. ∆lmeA also showed a small LM and LAM phenotype35. 
 
2.2 Antibiotic Sensitivity 
 LmeA has been predicted to be essential in M. tb and a previous study has shown that 
LmeA is upregulated during mouse infection36. It has been shown that when mycobacterial cells 
have short LM and LAM, antibiotic sensitivity increases37. These facts taken together with the 
short LM and LAM in the ∆lmeA mutant led us to investigate LmeA’s role in cell envelope 
integrity in terms of antibiotic sensitivity. Antibiotic sensitivity was determined through a 
resazurin-based assay. Resazurin is a colorimetric dye that can be used for viability dose-
response assays. As cells grow and produce reduced electron carriers, these reduced electron 
carriers can reduce resazurin, which is blue, to resorufin, which is pink. The 96-well plate can 
then be read at the appropriate wavelengths, and the output is run through an equation that 
translates the wavelengths into percent growth relative to a positive control. The percent growth  
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is then graphed and the inhibitory concentration that inhibits 90% of growth (IC90) is calculated, 
which is what is listed below in Table 1. All values were done in triplicate. 
Figure 2.1: The Reduction of Resazurin As cells grows and produce reduced electron carriers 
like NADH, these reduced electron carriers reduce resazurin (blue) to resorufin (pink). 
 
 
 
 
 
 
 
 Vancomycin Cefotaxime Ampicillin Clarithromycin Erythromycin 
WT 1.00 +/- 0.14 >100 >100 0.15 +/- 0.01 0.96 +/- 0.17 
ΔlmeA 0.39 +/- 0.04 9.77 +/- 2.08 
70.04 +/- 
14.77 
0.05 +/- 0.01 0.12 +/- 0.01 
ΔlmeA::Pnative-lmeA-
HA 
0.58 +/- 0.09 48.23 +/- 7.56 >100 0.15 +/- 0.01 0.31 +/- 0.01 
ΔlmeA::Phsp60-lmeA-
HA 
1.90 +/- 0.29 >100 >100 0.65 +/- 0.18 2.30 +/- 0.79 
WT::Phsp60-lmeA-HA 1.73+/- 0.41 >100 >100 0.71 +/- 0.38 5.85 +/- 0.9 
WT::Phsp60-lmeA-
HA (Episomal) 
2.13 +/- 0.33 >100 >100 0.25 +/- 0.05 0.92 +/- 0.21 
ΔpimE 0.24 +/- 0.01 84.41 +/- 3.78 >100 0.09 +/- 0.01 0.49 +/- 0.08 
S10 0.23 +/- 0.01 10.13 +/- 1.35 64.1 +/- 6.27 0.09 +/- 0.02 0.19 +/- 0.01 
S10::Phsp60-lmeA-
HA 
0.31 +/- 0.01 >100 >100 0.89 +/- 0.2 10.55 +/- 3.41 
S22 0.19 +/- 0.01 9.05 +/- 1.24 45.09 +/- 1.43 0.05 +/- 0.01 0.09 +/- 0.02 
Resazurin Resorufin 
 
NADH/H+ NAD+, H2O 
Table 2.1 Antibiotic susceptibility of various strains. IC90 values of various strains treated 
with a range of antibiotics at 37°C. Units in µg/ml. Green indicates increased antibiotic resistance 
relative to wildtype. Red indicates increased antibiotic sensitivity relative to WT.  
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 Treating M. tb infections requires the use of different classes of antibiotics with some 
targeting the cell envelope and others having cytoplasmic targets. For this reason, it was of 
interest to test a range of antibiotics. Vancomycin is a large antibiotic that binds to N-
acetylmuramic acid and N-acetylglucosamine, the building blocks of peptidoglycan, to inhibit 
the crosslinking of this layer38. Cefotaxime and ampicillin are beta-lactams that inhibit cell wall 
synthesis by binding to penicillin-binding proteins39. Cells with defective cell envelopes should 
show increased sensitivity to these antibiotics. Clarithromycin and erythromycin are small 
antibiotics with cytoplasmic targets. These two antibiotics are macrolides that bind to the 23S 
ribosomal RNA of the 50S subunit of the ribosome, inhibiting the transpeptidation and 
translocation step of protein synthesis40 . 
∆lmeA is more sensitive to all antibiotics tested relative to WT. When lmeA is 
complemented back with a native promoter to this knockout mutant, antibiotic sensitivity 
decreases. This complement is able to restore antibiotic resistance in the case of ampicillin and 
clarithromycin but does not fully restore in the case of vancomycin, cefotaxime, and 
erythromycin. When the ∆lmeA mutant is complemented with a heat shock protein 60 promoter 
granting constitutive expression, lmeA is expressed at a higher level than the native promoter, 
and antibiotic resistance increases. Antibiotic resistance is completely restored in the case of 
cefotaxime and ampicillin. This strain becomes even more resistant to antibiotics relative to WT 
in the case of vancomycin, clarithromycin, and erythromycin. When lmeA is expressed from the 
HSP60 promoter in a WT background, similarly increased levels of antibiotic resistance was 
observed. The strain remains resistant to cefotaxime and ampicillin, and becomes more resistant 
to vancomycin, clarithromycin, and erythromycin relative to WT. In the next strain, lmeA 
expressed was increased by expressing lmeA episomally using the heat shock protein 60 
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promoter in the WT background. The strain showed the highest resistance to vancomycin, 
maintained resistance to beta-lactams and erythromycin, and showed increased resistance to 
clarithromycin. Taken together, this data shows that the absence of LmeA leads to an increase in 
sensitivity to a range of antibiotics and the complementation and overexpression of LmeA leads 
to antibiotic resistance. 
Because lmeA was identified through finding suppressor mutants of ∆pimE, it was of 
interest to investigate how antibiotic sensitivity compares between ∆lmeA, ∆pimE, and the 
suppressor mutants. Both deletion mutants show an increase in antibiotic susceptibility but 
∆pimE is slightly more resistant to antibiotics compared to ∆lmeA, except in the case of 
vancomycin. Interestingly, in the case of the suppressor mutants S10 and S22 which are missing 
a pimE deletion and have non-functional LmeA, antibiotic sensitivity did not significantly 
increase relative to either of the single knockout mutants. Complementation of lmeA back into 
the S10 suppressor mutant did improve antibiotic sensitivity, even resulting in the highest 
antibiotic resistance for clarithromycin and erythromycin.  
Another avenue that was investigated in terms of antibiotic sensitivity was the effect of 
temperature. The previous antibiotic sensitivity table was done at 30°C. It was of interest to 
determine if increasing the temperature to 37°C, the temperature of the human body, would have 
a differential effect on WT relative to ∆lmeA. The tables below show the results. 
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Temp. 
(°C) 
 Vancomycin Cefotaxime Ampicillin Clarithromycin Erythromycin 
 
 
30 
WT 
1.51 +/- 
0.26 
>100 >100 0.49 +/- 0.09 3.52 +/- 1.08 
ΔlmeA 
1.00 +/- 
0.11 
>100 >100 0.14 +/- 0.01 0.82 +/- 1.03 
ΔlmeA::Pn
ative-lmeA-
HA 
0.37 +/- 
0.04 
>100 >100 0.05 +/- 0.01 0.25 +/- 0.05 
 
 
37 
WT 
1.00 +/- 
0.14 
>100 >100 0.15 +/- 0.01 0.96 +/- 0.17 
ΔlmeA 
0.39 +/- 
0.04 
9.77 +/- 
2.08 
70.04 +/- 
14.77 
0.05 +/- 0.01 0.12 +/- 0.01 
ΔlmeA::Pn
ative-lmeA-
HA 
0.58 +/- 
0.09 
48.23 +/- 
7.56 
>100 0.15 +/- 0.01 0.31 +/- 0.01 
Table 2.2: IC90s of Various Strains in 7H9 Media at 30°C vs 37°C IC90s in the presence 
of various antibiotics. Units are in µg/ml.  
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It is known that as the temperature increases, the fatty acid tails of phospholipids in the 
plasma membrane become less rigid, and this can lead to increased membrane fluidity. This 
corresponds to the general trend when looking at the above Table 2.2 When the temperature was 
increased to 37°C, WT and ∆lmeA became more sensitive to antibiotics. WT maintained its 
resistance to beta-lactams regardless of the temperature change. In the case of vancomycin, 
cefotaxime, ampicillin, and erythromycin, ∆lmeA’s percent change in IC90 from 30°C to 37°C 
was higher than WT’s. As seen before, this native promoter complement was unable to fully 
restore antibiotic sensitivity. At 37°C, the complement partially recovers antibiotic resistance. At 
30°C, the complement is unable to restore antibiotic resistance. 
In a previous publication, I determined the antibiotic sensitivity for WT in M63 media34. 
Later, for another project, I looked at antibiotic sensitivity in M63 media but this time leaving 
out Tween-80, the detergent typically used in mycobacterial cultures to mimic biofilm 
conditions. Table 2.3 demonstrates that adding and removing tween can drastically change 
antibiotic sensitivity in WT.  
 
 
 
  Vancomycin Cefotaxime Ampicillin Clarithromycin Erythromycin 
M63 – 
Tween 
>100 >100 >100 1.61 +/- 0.24 78.87 +/- 28.23 
M63 + 
Tween 
15.03 +/- 3.99 >100 >100 >100 >100 
Table 2.3: IC90s of Wildtype in M63 Media in the Presence and Absence of Tween-
80 IC90 values of wildtype treated with a range of antibiotics at 37°C. Units in µg/ml.  
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Following the confirmation of the effects of Tween-80 on the antibiotic susceptibility of 
wild type, the next step was to see if this trend held true for ∆lmeA. Below in Table 2.4 are the 
results. 
 
 
 
 
Using 7H9 media, tween was either added or removed and the IC90 of WT and ∆lmeA 
was determined. Without tween, antibiotic resistance increases in WT. Interestingly, the presence 
of tween does not make a different in IC90 in ∆lmeA as it does in WT. Tween interacts with the 
outside-most layer of the cell envelope- the capsule. This led us to believe that perhaps ∆lmeA 
already has a defective capsule, and so the addition tween makes no difference. 
 Another interesting pattern seen in Table 2.4 was that M63 was able to increase antibiotic 
resistance. The last of the antibiotic sensitivity tests was to see if M63 can increase antibiotic 
resistance in ∆lmeA in the same manner it does in WT. 
 
 
 
 
  7H9-Tween 7H9 + Tween 
WT 8 1.00 +/- 0.14 
∆lmeA 0.4 0.39 +/- 0.04 
Table 2.4: Vancomycin IC90s of WT and ∆lmeA in the Presence and Absence of 
Tween-80 in 7H9 Media at 37°C. Units in µg/ml. 
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Indeed, ∆lmeA was able to show increased resistance to antibiotics across the board when 
grown in M63 media without tween at 37°C.  WT became completely resistant to vancomycin, 
maintained resistance to the beta-lactams, and showed increased resistance to macrolides, 
erythromycin in particular. ∆lmeA became more resistant to antibiotics across the board as well, 
becoming completely resistant to beta-lactams. 
 
2.3 Cell Envelope Permeability 
 As shown in the previous section, ∆lmeA showed increased antibiotic sensitivity to a range 
of different antibiotics relative to WT. The next step in confirming this mutant’s defective cell 
envelope was to examine cell envelope permeability. Cell envelope permeability was determined 
through an ethidium bromide uptake assay. Ethidium bromide binds DNA located inside of the 
cell. If the cell envelope is more permeable, more ethidium bromide will bind to DNA and 
fluoresce. Fluorescence excitation at 530 nanometers and the resulting emission at 590 nanometers 
was measured over a time course and plotted. 
  Vancomycin Cefotaxime Ampicillin 
Clarithromyci
n 
Erythromyci
n 
WT >100 >100 >100 1.61 +/- 0.24 
78.87 +/- 
28.23 
∆lmeA 14.70 +/- 2.92 >100 >100 0.35 +/- 0.03 0.41 +/- 0.16 
∆lmeA::Pnati
ve-lmeA-HA 
99.60 +/- 
17.89 
>100 >100 0.61 +/- 0.02 9.51 +/- 1.64 
Table 2.5: IC90s of Various Strains in M63 Media IC90 values of various strains treated 
with a range of antibiotics at 37°C. Units in µg/ml. 
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Figure 2.2: Ethidium Bromide Permeability Assay 20 µM ethidium bromide uptake 
assay to measure cell envelope permeability in wildtype, ∆lmeA, and the complement 
strains. Time measured in minutes. *** indicates statistical significance 
 
 
 
∆lmeA had an increased uptake in rate and amount of ethidium bromide relative to WT 
and the complement. This data is in agreement with the antibiotic sensitivity data, indicating that 
∆lmeA indeed has a defective cell envelope 
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Figure 2.3: Ethidium Bromide Permeability Assay Wildtype, ∆lmeA, complements, 
and an overexpression strain were tested for permeability against 20 µM ethidium 
bromide. OE: overexpression. 
 
 
  
As in Figure 2.2, WT was the least permeable while ∆lmeA showed the most 
permeability. Interestingly, the lmeA overexpression strain did not decrease ethidium bromide 
uptake relative to WT the way the overexpression strain improved antibiotic resistance.  
 
2.4 Capsule Visualization 
 
 In Table 2.5, WT showed an increase in antibiotic resistance in the absence of tween, 
indicating that WT has an intact capsule that is disturbed by the presence of a detergent. ∆lmeA’s 
IC90 was unaffected by the presence of tween, leading us to speculate that the mutant already 
had a defective capsule. 
 To test this hypothesis, the capsule of WT and ∆lmeA was determined by the mannan and 
glucan binding FITC fluorescent-conjugated lectin, Concanavalin A and visualized using 
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fluorescence microscopy. No tween was used in the growing of these strains to minimize capsule 
disruption. Below are representative images of capsule staining.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.4: Capsule Visualization Capsules visualized using FITC-conjugated Concanavalin A 
binding lectin after one second exposure. 
 
As this data was reproducible, it is clear that ∆lmeA has a defective capsule. WT shows a 
mostly polar with some sidewall staining. ∆lmeA shows capsule staining through the length of the 
cell, but only on one side of the cell. This indicates that LmeA may play a role in the distribution 
of mannans and glucans in the capsule layer.  
Phase  Fluorescence  Merge  
WT  
ΔlmeA  
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LmeA has previously been shown to be important for MptA stabilization during stress 
conditions27. For this reason, we decided to investigate the capsule staining of a strain lacking 
mptA to see if it has a similar phenotype. To do this, we used an anhydrotetracycline (ATC)-
inducible promoter to silence the mptA gene. It was also of interesting to investigate an mptA 
knockdown strain in an ∆lmeA background to see which would have the dominant phenotype.  
 
 
 
Figure 2.5: Capsule Visualization The capsules of an mptA knockdown strain and an mptA 
knockdown ∆lmeA strain were visualized using Concanavalin A and fluorescent microscopy. 
 
 
The ATC-inducible mptA knockdown strain showed a unique phenotype relative to WT 
and ∆lmeA with no clear pattern for capsule staining. There seems to be patches with some foci 
all throughout the cell as opposed to the poles as seen in WT, or one-sided staining as in ∆lmeA. 
When ATC was added to the mptA knockdown ∆lmeA strain, the ∆lmeA phenotype was 
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dominant, showing only sidewall staining along one side of the cell. According to this one-sided 
sidewall staining, LmeA plays a unique role in capsule formation relative to MptA. 
 
2.5 Protein Expression During Starvation 
 Previously, it has been shown that LmeA plays an important role during stress conditions, 
including starvation27. For this reason, it was of interest to investigate general protein expression 
relative to WT in log and starvation conditions. This process was started by making sucrose 
gradients of WT and ∆lmeA during log phase and starvation in order to compare protein content 
in the cytoplasm, the IMD, and the PMCW. In a sucrose gradient fractionation, fractions one and 
two are cytoplasmic. Fractions four through six are IMD and the remaining fractions seven 
through twelve are PMCW. Next, a bicinchoninic acid (BCA) assay was done in triplicate to 
standardize protein content before loading onto an SDS-PAGE gel. After equal amounts of 
protein were loaded onto each lane of the gel, the protein profile was visualized by silver 
staining. 
 
 
 
 
 
Table 2.6: BCA Assay for Log-Phase Sucrose Gradient Fractions Values are wavelength 562 
nanometers. 
 
Table 2.7: BCA Assay for Starvation Sucrose Gradient Fractions Values are wavelength 562 
nanometers. 
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Figure 2.6: Silver Staining of WT and ∆lmeA Fractions 3-5 Log and Starvation Blue 
arrows indicate changes in specific protein bands. 
 
 
The above silver staining shows differential protein expression not only between WT and 
∆lmeA, but also between log and starvation phase. For fractions three through fractions five, ∆lmeA 
starvation seems to show increased protein content relative to WT log phase fractions, WT 
starvation fractions, and ∆lmeA log phase fractions. Although LmeA is a PMCW protein (fractions 
eight through twelve in a sucrose gradient), there are still changes in specific protein content that 
are pointed out by the blue arrows in the figure above. 
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Figure 2.7: Silver Staining of WT and ∆lmeA Fractions 6-8 Log and Starvation Blue arrows 
indicate changes in specific protein bands. 
 
 
In fractions six through eight, there are also changes in protein content between WT and 
∆lmeA. In fractions six, some of the upper bands and the lower thick band are upregulated in 
∆lmeA. The fractions further from the cytoplasm tend to have less protein, which is shown here 
by the low protein content in fractions seven and fractions eight. Changes in specific protein 
bands are indicated by the blue arrows in the figure above. 
 
 
 
 
 
L 
WT 
Log 
F6 
∆lmeA 
Log 
F6 
∆lmeA 
Star 
F6 
WT 
Star 
F6 
WT 
Log 
F7 
∆lmeA 
Log 
F7 
WT 
Star 
F7 
∆lmeA 
Star 
F7 
WT 
Log 
F8 
∆lmeA 
Log 
F8 
WT 
Star 
F8 
∆lmeA 
Star 
F8 
 25 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.8: Silver Staining of WT and ∆lmeA Fraction 10 Log and Starvation Blue 
arrows indicate changes in specific protein bands. 
 
As stated before, LmeA is a PMCW protein, so it was of interest to look at protein 
content changes in a PMCW fraction. Fraction 10 from each sucrose gradient underwent protein 
precipitation in order to visualize during silver staining. In these fractions, contrary to the pattern 
seen in Figure 2.6. In Figure 2.8, ∆lmeA starvation fractions do not have more protein content 
relative to the other samples. In fact, in this fraction, WT log has the most protein content. 
Specific changes in bands are indicated by the blue arrows. Taken together, these figures indicate 
that ∆lmeA changes the protein profile in different ways, depending on the cellular fraction 
location. 
 
 
 
L WT 
Log 
F10 
WT 
Star 
F10 
∆lmeA 
Log 
F10 
∆lmeA 
Star 
F10 
 26 
Chapter 3 
LmeA Localization and Cell-Envelope Binding Properties 
 
3.1 Previous Data Within This Aim 
 Understanding the binding behavior and localization of a protein can give important clues 
to its function. For this reason, it is of interest to investigate the binding of LmeA. Previously, it 
has been shown that LmeA binds phospholipids His-LmeA was purified from an IPTG inducible 
E. coli expression vector. In an ELISA setting, LmeA was able to bind to phosphatidylinositol, 
phosphatiphatidylethanolamine, and phosphatidic acid. Interestingly, LmeA was only able to 
bind to these lipids in the presence of E. coli lysate. LmeA-HA was also shown to localize to 
PMCW fractions in-vivo in a sucrose gradient setting35 . 
 
 
3.2 LmeA Binding in-vitro 
 LmeA is predicted to have a signal peptide and is secreted into periplasmic face of the 
plasma membrane (Figure 3.1). Whether or not the signal peptide gets cleaved or LmeA remains 
anchored to the plasma membrane is still unknown. To further investigate LmeA localization and 
binding, it is of interest to determine LmeA’s localization in-vitro, when it has a “choice” to bind 
to any cell envelope component as opposed to being trapped in its natural location, the 
periplasm. To investigate this, His-LmeA was purified from an IPTG inducible E. coli 
expression vector (Figure 3.2). The protein was purified via a nickel affinity column and eluted 
using an elution buffer containing HEPES and imidazole. 
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Figure 3.1: LmeA has a Predicted Signal Peptide Figure generated using SignalP 3.0. Neural 
network model. Signal peptide is likely cleaved between amino acid 27 and 28. 
 
  
 
 
 
  
 
 
 
 
 
 
 
Figure 3.2: Purification of LmeA from E. coli Expression Vector. L: Ladder, E: 
Elution, FT: Flowthrough. LmeA is a 29 kDa protein indicated by the blue arrow. 
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Next, this purified His-LmeA was added to WT cell lysate and incubated for half an hour 
at 37°C. LmeA was also added to buffer and ran identical to the sample as a control. These 
mixtures were then added to a sucrose gradient and fractionated after centrifugation. Each 
fraction was then run on an SDS-PAGE gel and a Western blot was done to probe for the protein 
of interest (Figure 3.4). The same lysate was used to probe for other cell envelope proteins to 
serve as markers for the cytosol, the IMD, and the cell envelope.  
 
Figure 3.3: Western Blot Localization of LmeA-HA In-vivo After Sucrose Gradient 
Ultra-Centrifugation. Figure by Kathryn Rahwles35. 
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Figure 3.4: Western Blot Localization of LmeA-HA in-vitro After Sucrose Gradient 
Ultra-Centrifugation 
 
 
 
 
LmeA showed differential localization in-vitro vs in-vivo. In-vivo, LmeA localized to 
fractions seven through twelve- PMCW fractions and co-localized with the PMCW marker, 
MptC. When LmeA was added to buffer and no cell lysate was present, it remained in cytosolic 
fractions and co-localized with a cytosol marker, Mpa. When LmeA was mixed with lysate, it 
bound to only IMD fragments and co-localized with the IMD marker, PimB’. This indicates that 
only plasma membrane, and not any cell wall component, is required for binding.  
 
3.3 LmeA Binds to Spheroplasts 
 To further investigate LmeA binding activity, spheroplasts were made from WT M. 
smegmatis cells. Glycine was used to inhibit the production of peptidoglycan and lysozyme was 
added to remove any existing peptidoglycan. Microscopy was done before and after these 
additions to confirm the presence of spheroplasts (Figure 3.5).  
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Figure 3.5: M. smegmatis cells before (left) and after (right) spheroplasting 
 
 Purified His-LmeA was then added to these spheroplasts and incubated for half an hour at 
37°C. This mixture was then placed atop a sucrose gradient, centrifuged, and fractionated. Each 
fraction was run on an SDS-PAGE gel, transferred to a membrane, and a Western blot was done 
to probe for the protein of interest as well as MptC, the PMCW marker, and PimB’, the IMD 
marker (Figure 3.6).  
Figure 3.6: His-LmeA and MptC Localization after Spheroplast Formation 
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In vitro in rod-shaped cells, LmeA localizes to fractions containing plasma membrane 
free of cell wall components and migrates differentially from the PMCW marker MptC. This 
indicated that only plasma membrane is necessary for LmeA binding, and that LmeA shows 
differential binding from typical PMCW proteins. This spheroplast binding assay (Figure 3.6) is 
a secondary confirmation of these previous findings. Indeed, LmeA was able to bind 
spheroplasts and also showed differential localization from the PMCW marker. Interestingly, 
PimB’, an IMD marker, was unable to be detected upon spheroplast formation.  
As another confirmation that LmeA binds spheroplasts, an ELISA was done. 
Spheroplasts were made and added to the bottom of the 96-well ELISA plate. To measure 
background binding, a negative control of isopropanol was added in place of spheroplasts. 
Purified LmeA was either mixed with untransformed E. coli lysate or not, and these mixtures 
were added. After incubation, the plate was read in a spectrophotometer at 650 nanometers. 
LmeA was able to bind to spheroplasts, with or without E. coli lysate although binding was more 
robust in the presence of the lysate. There was also some binding in the negative control. LmeA 
was able to bind to spheroplasts, with or without E. coli lysate although binding was more robust 
in the presence of the lysate. There was also some binding in the negative control. LmeA was 
able to bind to spheroplasts, with or without E. coli lysate although binding was more robust in 
the presence of the lysate. There was also some binding in the negative control 
As another confirmation that LmeA binds spheroplasts, an ELISA was done (Figure 3.7). 
Spheroplasts were made and added to the bottom of the 96-well ELISA plate. To measure 
background binding, a negative control of isopropanol was added in place of spheroplasts. 
Purified LmeA was either mixed with untransformed E. coli lysate or not, and these mixtures 
were added. After incubation, the plate was read in a spectrophotometer at 650 nanometers. 
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LmeA was able to bind to spheroplasts, with or without E. coli lysate although binding was more 
robust in the presence of the lysate. There was also some binding in the negative control.  
 
 
 
 
 
 
 
 
 
Figure 3.7: LmeA Binds to Spheroplasts in an ELISA Setting Values read at 650 nanometers. 
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Chapter 4 
LmeA’s Role in MptA Stabilization and Possible Interactions with ThiX 
 
4.1 Previous Data Within This Aim 
 It has previously been shown that during stress conditions, LmeA plays a role in MptA 
stabilization27 . During starvation and stationary phase, MptA degrades over time in ∆lmeA while 
MptA levels stay constant in WT. It has also been found that the transcription of lmeA is 
upregulated during stress conditions.  
 
4.2 ∆lmeA Has a Growth Delay After Starvation 
 As mentioned before, ∆lmeA does not have a growth delay under normal laboratory 
conditions. Since LmeA has previously been shown to play an important role during stress, it 
was of interest to determine if ∆lmeA struggles to recover after stress conditions. To do so, we 
grew WT and ∆lmeA to log phase, pelleted, washed, and resuspended in phosphate-buffered 
saline (PBS), starved for 24 hours, and placed back into 7H9 Middlebrook media to allow a 
chance for recovery. Optical density (OD) was measured every few hours to monitor growth 
(Figure 4.1).  
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Figure 4.1: ∆lmeA Has a Growth Lag After Starvation Percent change calculated 
with the following equation: % change = [OD2-OD1]/OD1 
 
∆lmeA did not grow at all for the first two hours after starvation. From two hours to six 
hours, WT and ∆lmeA grew at the same rate. From six to nine hours, ∆lmeA lagged in growth 
behind WT. Finally, between nine and twenty hours, ∆lmeA not only caught up in growth rate, 
but actually surpassed WT in growth. This data shows that ∆lmeA has a lag in growth that only 
occurs after stress.  
 OD is not the most reliable method to measure cell viability as cell debris and other 
factors can increase optical density, artificially inflating the growth rate. As a secondary 
confirmation, this recovery growth curve was done in a different format. Instead of using OD to 
monitor growth, resazurin was used to measure cell viability (Figure 4.2).  
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Figure 4.2: ∆lmeA Has a Growth Lag after Starvation In the photo on the right, the orange 
box indicates ∆lmeA replicates. The blue box indicates WT replicates. The green box indicates a 
negative control containing only media and resazurin. Photo taken at the 1.5 hour mark. On the 
left, y-axis shows percent growth normalized to WT.  
  
These results show that ∆lmeA indeed does have a growth lag after a twenty-four-hour 
starvation period. When using the OD values from the spectrophotometer to read the 96-well 
plate, these values are converted to percent viability using an equation that requires a no-drug 
control. Since this is not a dose response assay, there is no no-drug control and instead, WT’s 
average OD value was used for this number since WT’s growth rate represents the non-variable 
growth rate. In other words, ∆lmeA was normalized to WT. It takes three hours for ∆lmeA to 
return to a normal growth rate. This can be visually seen in right panel of Figure 4.2, where 
∆lmeA is much bluer than WT, indicating less growth.  
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4.3 Investigating LmeA as a Possible Thioredoxin Reductase 
 lmeA shares an operon with one other gene- MSMEG_5786. According to bioinformatics, 
this gene encodes a putative thioredoxin. Thioredoxins are small redox proteins that are present in 
nearly all organisms. Thioredoxins operate by reducing disulfide bridges between cysteines in 
other proteins. They are typically characterized by their CXXC amino acid motif and have a 
characteristic thioredoxin fold in their tertiary structure. MSMEG_5786 (thiX) is 465 base pairs 
long and encodes a protein that 16260.6 daltons. thiX is well conserved in mycobacteria, with the 
characteristic CXXC motif present throughout M. tuberculosis, M. smeg, M. leprae, M. bovis, and 
M. marinum (Figure 4.3). The ortholog in M. tb is Rv0816c. 
 Operons are two or more genes that share the same promoter and are transcribed 
simultaneously as one large mRNA. Genes are typically grouped in operons when they encode 
proteins that share a common purpose. Because of this coupled with the fact that LmeA has been 
shown to play a role in stress response, it is of interest for us to investigate LmeA’s relation to 
ThiX.   
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Figure 4.3: thiX is a Conserved Gene Throughout Mycobacteria Top panel shows 
ThiX’s location in the operon. Bottom panel shows homology between species of 
mycobacteria. Top panel generated via Mycobrowser.com. Bottom panel generated by 
NCBI Protein Blast. Red box indicates conserved CXXC motif that is characteristic of 
thioredoxins. 
 
 
 
 
One possible hypothesis is that LmeA acts as a thioredoxin reductase, reducing ThiX. 
Going off this theory, it is possible that ThiX is responsible for degrading MptA in ∆lmeA during 
stress conditions. Interestingly, MptA has well conserved cysteine residues that could possibly be 
forming disulfide bridges for this thioredoxin to reduce (Figure 4.4). 
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Figure 4.4: MptA has Conserved Cysteine Residues Throughout Mycobacteria Figure 
generated using NCBI Protein BLAST. Boxes indicate conserved cysteines residues that could 
form possible disulfide bridges. 
  
To investigate this, we decided that two new strains should be made: lmeA-HA-∆thiX and 
∆lmeA-∆thiX. These strains can be used for a variety of assays to check for changes in LmeA 
localization and MptA levels during stress conditions. The first step was to design primers for 
HiFi cloning and amplify upstream and downstream of the genes of interest using polymerase 
chain reactions (PCR).  
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After successful PCR amplification, the fragments were purified via PCR cleanup and the 
proper fragments were inserted into a digested vector via HiFi cloning according to the construct 
wanted. This ligated plasmid was then heat shocked into competent Escherichia coli cells and 
grown on lysogeny broth (LB) plates containing hygromycin to select for the plasmid containing 
a hygromycin resistant cassette. Colonies were picked and grown in TBK liquid medium 
planktonically at 37°C overnight. These candidate plasmids were purified from the cells and 
digested with HindIII restriction enzyme to confirm the construct. 
 
 
 
 
 
 
 
Figure 4.5: PCR Amplification of Upstream and Downstream 
Genes of Interest L: Ladder. Lanes 1, 2, 3: lmeA upstream, 952 bp 
expected size. Lanes 4, 5, 6: thiX downstream, 1034 bp expected size. 
Lanes 7, 8, 9: thiX upstream, 1020 bp expected size. 
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Candidate plasmids showing the proper band sizes after restriction enzyme digest were 
sent for Sanger sequencing for secondary confirmation and both plasmids came back as the 
confirmed construct. As of this thesis being written, only ∆lmeA-∆thiX has been successfully 
electroporated into electrocompetent M. smegmatis cells. The colonies from electroporation were 
confirmed for the double crossover event via sucrose sensitivity and hygromycin resistance and 
frozen stock was made. Genomic DNA was extracted, and primers were designed outside the 
inserted region to confirm the strain. The PCR came out successfully and two identical strains 
were confirmed to be our constructs. No testing has yet been done on this strain. 
Figure 4.6: HindIII Restriction Enzyme Digest of Candidate 
Plasmids Top Panel: ∆lmeA-∆thiX candidates, expected size: 3163 bp 
& 6747 bp. Plasmid #2 chosen and sent for sequencing. Bottom Panel: 
lmeA-HA-∆thiX candidates. Expected size: 3163 bp, 5729 bp. Plasmid 
#1 chosen and sent for sequencing. 
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An AMB Master’s student, Audrey Della Valle, has cloned thiX into an E. coli 
expression vector and successfully purified ThiX. I am in possession of purified LmeA. LmeA 
will be tested for thioredoxin reductase activity by testing to see if the protein is able to reduce 
5,5'-dithiobis-(2-nitrobenzoic acid) using NADPH as a source of electrons. ThiX will be tested 
for thioredoxin activity against insulin. 
 
 
 
 
 
 
 
 
Figure 4.7: PCR Amplification of Extracted Genomic DNA to 
Confirm Double Knockout Strain L: Ladder. Lanes 1 & 2: Upstream 
fragment, expected size 1057 bp. Lanes 3 & 4: Primer set #1 to amplify 
downstream fragment, expected size 1012 bp. Lanes 5 & 6: Primer set 
#2 to amplify downstream fragment, expected size 1134 bp. Lanes 7 & 
8: Primer set #3 to amplify downstream fragment, expected size 835 bp. 
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Chapter 5 
Discussion and Future Directions 
 
This study aimed to further characterize LmeA by investigating antibiotic sensitivity, cell 
envelope permeability, protein expression during different conditions, capsule staining, binding, 
and its interactions with other proteins. Although this study made advances in the 
characterization of this protein, LmeA’s exact function remains unclear. 
 It is interesting to note that although the suppressor mutants (∆pimE with a point 
mutation in lmeA rendering it non-functional) restore colony size, the suppressor mutants do not 
recover in any other aspect. They are still sensitive to antibiotics, still more permeable to 
ethidium bromide relative to wildtype, and still have shorter lipomannan and 
lipoarabinomannan35. Perhaps it would be of interest to further study the relationship between 
this restored colony size with these altered phenotypes- why only colony size is restored when 
seemingly all other tested phenotypes do not recover. It is also interesting to note that these 
suppressor mutants do not become more sensitive to antibiotics relative to ∆pimE or ∆lmeA. One 
would assume that not having both of these functional proteins would compound and exacerbate 
the already defective cell envelope and increase antibiotic sensitivity. Perhaps this could be 
another route of investigation. 
 ∆lmeA became more sensitive to antibiotics. This was expected because this mutant is 
unable to produce mature LM and LAM- important components for cell envelope integrity. Less 
expected was the increased antibiotic resistance seen in the three overexpression strains. 
Previously, it has been shown that in these overexpression strains, LM and LAM are more 
abundant. This leads us to conclude that the wildtype cell envelope has room for improvement- 
apparently increasing the abundance of LM and LAM translates into a more fortified cell 
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envelope. One study showed that lmeA is upregulated upon M. tb infections in mice, and this is 
in accordance with the pattern we are seeing. It is also worth noting these strains have different 
responses to antibiotics, depending on the antibiotic’s target. In the lmeA overexpression strains, 
antibiotic sensitivity increased at a rate higher in macrolides than antibiotics with cell envelope 
targets. It is also worth noting that in the suppressor mutant strain complemented with 
overexpressed lmeA, antibiotic resistance is at an all-time high for erythromycin relative to the 
other strains tested. Another point to note is the difference in antibiotic sensitivity between 
clarithromycin and erythromycin. They are both macrolides- in fact, clarithromycin is just the 
new generation of erythromycin. Clarithromycin has been shown to be several-fold more active 
in-vitro than erythromycin. This supports the trend seen in the antibiotic resistance table. 
Clarithromycin resistance only increases six-fold at its peak while erythromycin increases ten-
fold at its peak. Another point to be made with this antibiotic sensitivity data is its relation a 
previously done transposon mutagenesis. Wildtype and ∆lmeA underwent a transposon 
mutagenesis assay. As one can see below in Figure 5.1, ∆lmeA had fewer insertions in 
MSMEG_2584, a gene encoding a putative penicillin binding protein. This data is in accordance 
with the antibiotic sensitivity data showing ∆lmeA is sensitive to beta-lactams. 
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Figure 5.1: Transposon Mutagenesis Data Experiment done by Kathryn Rahlwes and analyzed 
by Hiro Kado. 
 
It is also interesting to discuss temperature’s effect on ∆lmeA. At higher temperatures, the 
fatty acid tails of phospholipids in the plasma membrane become less rigid, and this can lead to 
increased membrane fluidity. From 30°C to 37°C, ∆lmeA showed increased antibiotic sensitivity 
by more than 2.5-fold in the case of vancomycin while WT only increased by 0.5-fold. Perhaps 
the lack of LM and LAM exacerbates this membrane fluidity that follows an increase in 
temperature. It is unclear why the native complement struggles to restore antibiotic resistance. 
Perhaps it is the L5 integration site of the complemented lmeA gene that is responsible for this. 
This issue is exacerbated at 30°C- something that is not seen at 37°C. A western blot comparing 
LmeA-HA levels at these two temperatures would easily solve this question. 
 The presence or absence of the detergent tween did not have an effect on ∆lmeA antibiotic 
sensitivity, while WT was greatly affected. Since tween only physically interacts with the capsule, 
it leads us to believe that our mutant already has a defective capsule. If ∆lmeA naturally has a 
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defective capsule, the disturbance from tween will not have a significant effect on antibiotic 
sensitivity. The capsule staining that was done supports this hypothesis. Wildtype capsule staining 
showed mostly polar with some sidewall staining. ∆lmeA had a unique phenotype that showed the 
length of the sidewall being stained, but only on one side. This phenotype has been reproduced in 
three separate experiments. In addition, this ∆lmeA capsule phenotype is the dominant phenotype 
in an mptA knockdown-∆lmeA strain. This leads us to believe that perhaps LmeA is involved in 
the distribution of mannoses and glycans in the capsule, or that it stabilizes a protein that serves 
this function. Further investigation is needed into this theory.  
 M63 media without tween was able improve ∆lmeA’s sensitivity to various antibiotics. WT 
recovered greatly in the case of vancomycin and erythromycin while ∆lmeA recovered less 
significantly across the different classes of antibiotics. In accordance with all of this antibiotic 
sensitivity data, ∆lmeA is more permeable to ethidium bromide. Taken together, this mutant has a 
clearly defective cell envelope. 
 Protein expression in WT and ∆lmeA is different, whether in log phase or starvation. In 
earlier fractions, ∆lmeA has increased protein content in starvation lanes relative to any of the other 
conditions. In later fractions, this trend does not seem to hold true. This is interesting because 
LmeA is a PMCW protein, localizing to fractions seven through twelve. For this reason, it was 
surprising to see differences in protein content throughout the different parts of the cell. The four 
sucrose gradients used for this experiment were made by three different people in the Morita lab. 
I have re-made all four sucrose gradients in my hands to minimize variability in preparation. These 
sucrose gradients have yet to be visualized via silver staining, but this will be a next step. 
 We know that LmeA is a PMCW protein because in-vivo, it localizes to PMCW fractions 
in sucrose gradients. The localization and binding of a protein can give clues to a protein’s 
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function, so fully investigating binding was of interest. LmeA has a signal peptide. This signal 
peptide can either be cleaved, or it can remain and anchor the protein to the cell envelope; it is 
unclear which is the case. To investigate, purified LmeA was added to cell lysate, incubated, ran 
on a sucrose gradient, fractionated, and then ran on a Western blot. Probing for His-LmeA showed 
that LmeA bound to IMD fractions, or plasma membrane free of cell wall fractions. This indicated 
that LmeA has no preference for cell wall components. This could lead one to believe that the 
signal peptide does not get cleaved off, and LmeA remains anchored interacting with the plasma 
membrane. If the signal peptide got cleaved off, LmeA would be free to float around the periplasm, 
perhaps having some interaction and thus affinity for the next layer- peptidoglycan.  
An experiment that would give us a definitive answer to this question is to visualize LmeA 
in-vivo under the microscope. The issue with this is that LmeA is a small, 29 kDa protein that 
would not take well to a large fluorescent protein tag. LmeA is periplasmic, so using a tagged 
LmeA strain to do immunofluorescence would not work. The solution to this is to remove all the 
layers of the cell envelope from peptidoglycan upwards and to do immunofluorescence with a 
tagged LmeA strain. We have attempted to do this, successfully forming spheroplasts in the 
process but we have been unable to produce a reproducible result. If LmeA is anchored to the cell 
envelope, we should see fluorescence. If LmeA’s signal peptide gets chopped off, then LmeA 
should float away into the media upon the removal of peptidoglycan. This is a future direction that 
needs to be finished. 
One clue that is in agreement with all previous binding data is that LmeA binds 
spheroplasts. Spheroplasts contain just plasma membrane. LmeA binds spheroplasts both in a 
sucrose gradient setting and an ELISA setting. It is interesting to note that even in spheroplasts 
where there is no cell wall, LmeA still migrates to different fractions from our PMCW marker 
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MptC. It is also interesting to note that based upon this experiment and other experiments done 
for a different project, IMD proteins seems to disappear upon the formation of a spherical cell. 
This could branch out to form a small side project- whether or not the IMD is shape dependent. 
In the ELISA-based spheroplast binding assay, it was interesting to see that LmeA could bind 
spheroplasts with or without E. coli lysate, although binding was better with it. It was also 
interesting to note that untransformed E. coli lysate was used and binding still occurred. Previous 
data has shown that in order for LmeA to bind to phospholipids, transformed E. coli was 
required. 
LmeA has previously been shown to be important for MptA stabilization during stress 
conditions. Consistent with this data is the above growth recovery curve after starvation. ∆lmeA 
does not have a growth lag when grown in normal conditions. This phenotype is specific to stress. 
Perhaps the lack of MptA during these conditions leads to a decrease in doubling rate. An 
experiment to test this would be to see if ∆mptA has a growth lag during starvation. If it does and 
it is similar to the timing of LmeA, this would tell us that this growth lag is an MptA dependent 
phenomenon. If it does not have a growth lag, it would tell us this phenotype is specific to LmeA. 
Previous data has shown that an mptA knockdown strain does not have a growth lag. 
One possibility of LmeA’s function is that it is a thioredoxin reductase. This speculation 
was partially generated based on the fact that LmeA shares an operon with thioredoxin. Genes that 
share an operon typically operate in the same system. In addition, MptA has conserved cysteine 
residues that could possibly form disulfide bridges. Perhaps LmeA protects MptA from ThiX-
mediated degradation.  
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A few experiments have to take place for this to above model to be confirmed. First, 
purified LmeA needs to be tested for thioredoxin reductase activity. Second, purified ThiX needs 
to be tested for thioredoxin activity. Both proteins have been expressed and purified from E. coli 
expression vectors, so the assay just needs to be done. After this, a next step would be to use the 
∆lmeA-∆thiX strain made in this study to see if MptA degradation occurs during starvation. If ThiX 
is responsible for MptA’s degradation during starvation in ∆lmeA, then no degradation should 
occur during starvation in this double knockout strain. Another possible step could be to get the 
crystal structure of MptA to confirm these possible disulfide bridges. MptA currently does not 
have crystal structure due to the fact that it is a membrane protein, which are infamous for being 
Figure 5.2: Model for LmeA as a Possible Thioredoxin Reductase In this 
hypothesis, under active growth, LmeA interacts with MptA to produce full length 
LM/LAM. During stress conditions, LmeA protects MptA from stress-induced-
thioredoxin-mediated degradation, allowing for the biosynthesis of mature 
LM/LAM. In ∆lmeA, ThiX degrades MptA, resulting in immature LM/LAM. 
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difficult to accurately crystallize. Preliminary data may support this hypothesis. An easier way to 
test for disulfide bridges would be to use a commercially available fluorescent dye that binds to 
disulfide bonds. A previous student performed thiol trapping on MptA in the ∆lmeA strain and 
showed that MptA contained no disulfide bonds relative to WT. This experiment needs to be 
repeated with additional control, such as using the ∆thiX strain to see if the phenotype is the same, 
confirming our hypothesis. Another experiment would be to perform thiol trapping on the ∆lmeA-
∆thiX strain to see if these disulfide bonds remain absent in MptA. 
Another interesting future direction would be to use the lmeA-HA-∆thiX strain to see if 
LmeA localization changes in the absence of ThiX. Perhaps LmeA’s sole function is to protect 
MptA from degradation and if ThiX is not present, LmeA could be downregulated or its 
localization could change. mRNA transcripts of lmeA for this strain could be done to check for 
lmeA levels as well as a sucrose gradient to check for changes in localization. Looking back at 
Figure 5.1, ∆lmeA has fewer insertions in MSMEG_5470c which encodes for molybdopterin 
biosynthesis protein MoeA 1. This protein is involved in redox reactions, as is ThiX. Literature 
has shown that ThiX has physical interactions with MoeA in other organisms such as E. coli, and 
programs like string tie together thioredoxins with redox proteins related to MoeA.  
There are many clues to LmeA’s exact function but still no smoking gun. With the purified 
ThiX and the knockout strain that were made, LmeA’s role in cell envelope biosynthesis could be 
determined soon. 
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Chapter 6 
Methods 
 
6.1 Bacterial Strains and Growth Conditions 
 
 Wild-type (WT) M. smegmatis mc2155 (Snapper et al.1990), ΔpimE, ΔpimE::pimE41 , 
ΔlmeA, ΔlmeA::Pnative-LmeA-HA, ΔlmeA::Phsp60-LmeA-HA35  were grown in 130 rpm 
planktonic conditions at 30°C or 37°C in a liquid culture of Middlebrook 7H9 manufactured by 
Becton Dickinson. 7H9 was supplemented with 0.2% glycerol, 0.2% glucose, 15 mM NaCl, and 
0.05% tween. Other cultures were grown in M63 minimal media, of which the recipe can be 
found in Eagen et al. 201834 . Culture was grown to log phase (OD600 0.6-1). For starvation 
conditions, once log phase was reached, the cultures were spun down at 4000 rpm for 5 minutes, 
washed with sterile phosphate-buffered saline, spun down as described before, resuspended in 
the original volume in sterile phosphate-buffered saline, and starved for 24 hours. For the 
recovery assay, cultures in PBS were spun down as described above and resuspended in 7H9 
complete media, as described above and OD600 was monitored. 
 
 
6.2 Antibiotic Sensitivity Assay 
 
 Frozen stocks with known colony forming units (cfu) were prepared for all tested strains 
by growing cells to an OD600 reading between 0.5 and 1.0 in Middlebrook 7H9 or M63, and 
frozen in aliquots with a final concentration of 15% (w/v) glycerol at –80°C. In 96-well 
microtiter plates, antibiotics were serially diluted in 100 μl of media and mixed with cells from 
the frozen stocks to achieve the final density of 5.0 × 103 cfu/mL. The plates were incubated in a 
humidity chamber either at 30 °C or 37°C. After a 24 hour 32 hour incubatiom, 20 μL of filter-
sterilized 0.015% (w/v) resazurin solution was added to each well to initiate colorization. After 
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additional 8 hour (37°C) or 13.5 hour (30°C) incubation, the plates were read on a 
spectrophotometer at 570 and 600 nm. Percent difference in cell viability between antibiotic-
treated and control cells was calculated using the formula: (O2 × A1 – O1 × A2)/(O2 × P1 – O1 
× P2) × 100, where O1 and O2 are molar extinction coefficient of resazurin (oxidized form) at 
570 and 600 nm, respectively; A1 and A2 are absorbance of test wells at 570 and 600 nm, 
respectively; and P1 and P2 are absorbance of positive control well at 570 and 600 nm, 
respectively. The IC90 values were calculated using OriginPro 9.1 data analysis software. 
 
6.3 Ethidium Bromide Uptake Assay 
 Ethidium bromide uptake assay was done in accordance to Eagen et. Al, 201834. Briefly, 
log phase (OD600 = 0.5–1.0) cells grown in 7H9 were centrifuged and pellets were resuspended 
at an equal OD600 reading in 50 mM KH2PO4 (pH 7.0) and 5 mM MgSO4. Cells were then 
incubated for 5 min with 25 mM glucose, transferred to an opaque, black 96-well microtiter plate 
(Brand Tech Scientific), and mixed with 20 μM of ethidium bromide. Fluorescence was 
measured with an excitation wavelength of 530 nm and an emission wavelength of 590 nm. 
6.4 Capsule Staining 
 20 mL primary cultures were inoculated into Middlebrook 7H9 supplemented with 0.2% 
glycerol, 0.2% glucose, 15 mM NaCl, without tween and grown at 37°C. After 3-4 days, 
secondary cultures were inoculated, also without tween. After 16-18 hours, cells were pelleted at 
4000 rpm for 5 minutes and resuspended in 450 µL of PBS and 50 µl of 2 mg/ml of FITC-
fluorescent-conjugated lectin Concanavalin A suspended in 0.1M sodium bicarbonate and 
incubated for 30 minutes at 37°C. The solution was spun down at 12000 rpm for three minutes, 
washed with PBS, and spun again. The final pellet was suspended in resuspended in 100 µl PBS. 
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5-10 µl of this solution was pipetted onto a 1% agarose in 7H9 gel pad atop a glass slide and 
visualized via fluorescent microscopy.  
 
6.5 Silver Staining 
 A BCA assay was first done to determine protein content per sucrose gradient fraction. 
10 µL of each sample was added to a 96 well plate. 200 µL of the Pierce BCA Protein Assay Kit 
was added to each well and incubated in the dark for 30 minutes at 37°C. The plate was then read 
in a spectrophotometer at 562 nm. These values were then used to standardize protein content 
before silver staining. 12 µL of each sucrose gradient fraction standardized for protein content 
was mixed with 4 µL of loading buffer and boiled at 95°C for five minutes. Each sample was 
then loaded onto a 12% acrylamide SDS-PAGE gel and ran at 150V. The gel was incubated with 
a fixative solution for 45 minutes and washed three times with Milli-Q water. The gel was then 
incubated a sensitizing solution for 2 minutes and washed with water for 5 minutes. The gel was 
then incubated with a silvering solution fo r45 minutes and rinsed for 20 second with water 
afterwards. A developer solution was added for 6-8 minutes until the stop solution was added to 
stop the reaction.  
 
 
6.6 LmeA Purification 
 
 Protocol by Kathryn Rahlwes. E. coli BL21 cells transfected with pMUM 121 was 
inoculated into 20 mL TBK with 100 µg/ml ampicillin and grown at 37°C overnight. 5 mL was 
inoculated into 500 mL TBK and incubated at 30°C planktonically at 130 rpm until OD600 
reached 0.6. A final concentration of 1 mM IPTG was added. 
 After 3 hours of incubation with IPTG, the culture was spun down at 8000 rpm for 10 
min at 4°C. Supernatant was discarded and pellet was resuspended in 40 mL PBS and transferred 
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to a 50 mL conical tube. Weight of pellet was measured. Add 1 mL of lysis buffer (see recipe 
below) per 0.25 g pellet. Incubate 10 min at room temperature. Sonicate on ice for 10 sec and 
repeat five times, keeping on ice in between sonications. Transfer sonicated sample to 15 mL 
conical tube and centrifuge for 30 min at 4°C. Transfer supernatant and spin again. Filter 
supernatant though 0.22 µM syringe filter to remove any remaining cell debris. 
 LmeA was purified from an E. coli IPTG inducible expression vector using a nickel 
affinity column. LmeA purification materials used include Ni NTA Resin (GoldBio, H-250-25), 
20 mM HEPES pH 7.5, Amicon Ultra-4, Lysis buffer (3.9 mL of 50 mM HEPES pH 7.5, 200 
mM NaCl, 50 µL 100 mM PMSF in 50 mM HEPES pH 7.5, 50 µl 100 mM DTT, 500 µL 10 
mg/ml Lysozyme), wash buffer (100 mM HEPES pH 7.5, 10 mM imidazole, 500 mM NaCl), 
elution buffer 1 (100 mM HEPES pH 7.5, 75 mM imidazole, and elution buffer 2 (100 mM 
HEPES pH 7.5, 125 mM imidazole), elution buffer 3 (100 mM HEPES pH 7.5, 250 mM 
imidazole). 250 µl of bed volume of Ni NTA Resin was loaded onto a 15 ml column and washed 
with 5 volumes of wash buffer. 10 mL of lysate was incubated in this overnight at 4°C while 
rotating. The next day, the column was opened and the flow through was collected. Wash the 
resin with 1 mL of wash buffer plus 0.05% tween. Wash three times with wash buffer without 
tween. Elute penta-His-tagged-LmeA using 200 µL elution buffer 1, then elution buffer 2, then 
elution buffer 3. Repeat until 15 fractions are collected. Run all samples on SDS-PAGE and 
visualize with Coomassie Brilliant Blue. Fractions containing peak His-LmeA are combined, 
concentrated, washed three times with 20 µM HEPES pH 7.5, and resuspended in a final volume 
of 1 mL containing 20% glycerol.  
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6.7 In-vitro and In-vivo Sucrose Gradient Fractionation 
 
 2.5 mL of primary cultures were inoculated into three 500 mL cultures containing 7H9 
complete. After 16-18 hours of planktonic growth at 37°C, or until the OD600 reaches 0.6-1. 
These cultures were then spun down at 8000 rpm for 15 minutes at 4°C. The supernatant was 
poured off and the pellets were resuspended in 50 mM Hepes/NaOH (pH 7.4), spun again as 
above, and resuspended in 5 ml of lysis buffer per 1 gram of wet pellet. Lysis buffer: 25 mM 
Hepes (pH7.4), 20% sucrose in 25 mM Hepes, 2 mM EGTA. 1/25 volume lysis buffer of 
protease inhibitor was added. 2200 psi of nitrogen gas for thirty minutes was applied to this 
mixture three times to lyse cells. The lysed cell mixture was centrifuged for 4000 rpm for 10 min 
at 4°C. The supernatant was removed and centrifuged as before. 1200 µL of this solution was 
placed atop a 20-50% sucrose gradient and centrifuged at 35000 rpm for 6 hours at 4°C. For the 
in-vitro experiment, 1 mg/mL of purified protein was added and incubated at 37°C for 30 
minutes before loading onto the sucrose gradient. The gradient was then fractionated into 13 
fractions and stored at 80°C. 
 
6.8 ELISA Spheroplast Binding Assay 
 Either spheroplasts or isopropanol were added to the bottom of an ELISA plate. The plate 
was evaporated without the lid at 37°C for 2 hours. 20 µL of hexanes was added to all wells to 
block and evaporated in a fume hood for 20 minutes. 5% milk was then added for 16-19 hours at 
4°C without shaking with the cover. The wells were washed twice for five minutes with 200 µL 
of PBST. 10 µL of 1 mg/mL protein was added to each well and incubated for two hours at 
37°C. The wells were washed with 200 µL PBST for 5 minutes at room temperature three times. 
50 µL of 1:4000 penta-his primary antibody was added to each well and incubated for one hour 
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at room temperature. Each well was washed with 200 µL PBST for five minutes three times. 100 
µL of TMB colorization reagent was added to each well and incubated for one hour at room 
temperature in the dark. The plate was then read at 650 nm. 
 
6.9 Post-Starvation Growth Recovery Curve  
 WT and ∆lmeA were inoculated into 20 mL cultures containing Middlebrook 7H9 
supplemented with 0.2% glycerol, 0.2% glucose, 15 mM NaCl, and 0.05% tween and grown for 
3-4 days planktonically at 37°C. Secondary cultures were then innoculated and grown for 16-18 
hours or until an OD600 of 0.6-1.0 was reached. The cultures were were spun down at 4000 rpm 
for 5 minutes, washed with sterile phosphate-buffered saline, spun down as described before, 
resuspended in the original volume in sterile phosphate-buffered saline, and starved for 24 hours. 
For the recovery assay, cultures in PBS were spun down as described above and resuspended in 
7H9 complete media, as described above and OD600 was monitored. 
 
6.10 Making Spheroplasts 
 A secondary culture of M. smegmatis was grown at 37°C until an OD600 of 0.6-1 was 
reached. Glycine was added to the culture to a final concentration of 1.2% (w/v) and incubated 
for another 20-24 hours. The culture was then centrifuged at 4000 rpm for 5 minutes and washed 
with Spizizen’s minimal medium (SMM), spun again above, and resuspended in SMM at the 
original volume of the culture. A filter sterilized solution of 5 mg/ml lysozyme at 20% w/v and 
glycine at 1.2% w/v was added. The culture was incubated for another 20-24 hours. The 
formation of spheroplasts was confirmed by microscopy. 
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6.11 Polymerase Chain Reaction (PCR) Amplification 
For PCR amplification to generate inserts for ligation, each tube contained the following: 
12.8 µl of Pre-Mix (8.8 µL water per tube, 3.2 µl 5x Phusion HF buffer per tube, 0.4 µl 10 mM 
dNTPs per tube, 0.4 µl 0.1 ng/µl genomic DNA per tube), 1 µL each of forward/reverse primer, 
0.8 µL DMSO, and 0.4 µL water. After heating to 98°C, 4 µL of hot start mix was added to each 
tube (3 µL water per tube, 0.8 µL 5x Phusion HF buffer per tube, 0.2 µL Phusion DNA 
Polymerase per tube). The reaction continued thirty times. The resulting DNA was run on a 1% 
agarose gel and visualized via ethidium bromide incubation and UV light.  
For PCR amplification to confirm extracted M. smeg genomic DNA, the above 
concentrations were used with an added 4 µL of extracted DNA. DNA was extracted by 
incubating frozen stock for 30 minutes on a 95°C heating block. The sample was micro 
centrifuged at 16000 rpm for 2 minutes and the supernatant was transferred to a new tube. 200 µl 
of 24:1 (w/v) chloroform/isoamyl alchol mix was added to the sample and briefly vortexed to 
extract proteins and lipids. The sample was placed on ice and 1/10 volume of 3M sodium acetate 
and 2.5 volumes of ice-cold 100% ethanol was added. The sample was micro centrifuged for 5 
minutes at 4°C, the supernatant was poured off, and and the pellet was air-dried until all ethanol 
was evaporated. The pellet was resuspended in 100 µL milliQ water.  
PCR clean-up was done with a Qiagen QIAquick Gel Extraction kit. 5 volumes of Buffer 
PB was added to the sample and 3M Na-Acetate (pH 5.0) was added until sample turned yellow. 
Sample was applied onto a QIAquick column and spun for 1 minute and repeated. The column 
was washed with 750 µL Buffer PE and incubated for 2-5 minutes before spinning. The column 
was transferred to a new tube and the DNA was eluted with pre-warmed (60°C) Buffer EB that 
was incubated for 5 minutes at room temperature before spinning. 
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6.12 HiFi Assembly 
 First the DNA concentrations of digested vector and inserts were measured using 
Nanodrop. For DNA ranging from 0.03-0.2 pmol, the ratio of vector to insert was 1:2. The 
following equation was used for calculations: pmols = (weight in ng) x 1000 / (base pairs x 650 
daltons). After calculating and mixing the proper ratio of vector to insert, 1 volume of NEBuilder 
Master Mix was added and the sample was incubated for 15 minutes at 50°C. 5 µl of this plasmid 
was added to 250 µL of E. coli lab-made competent cells and placed on ice for 30 minutes. Then 
the cells were heat shocked at exactly 42°C in.a water bath for 45 seconds. The sample was 
placed on ice for 2 minutes and 950 µL of room temperature SOC broth was added to each tube. 
The sample was incubated for 60 minutes at 37°C. 100 µL of this mixture was pipetted onto 
selection plates containing the proper antibiotic and incubated overnight at 37°C. Colonies were 
picked and grown in 2 ml of TBK media with proper antibiotic overnight. The cells were 
pelleted and the supernatant was poured off. The pellet was resuspended in ice-cold 200 µL 
Qiagen Buffer P1. 200 µL of Buffer P2 and P3 were added to the sample and inverted to mix. 50 
µl chloroform was added and vortexed. The sample was spun down at 4°C and the upper phase 
was transferred to a new tube. 1/10 volume 3M Na-acetate (pH 5.2) was added and DNA was 
precipitated by adding 2 volumes of ice-cold ethanol and inverted to mix. Plasmid DNA was 
collected by spinning at max speed at 4°C for 10 minutes and the supernatant was removed. 1 
mL of ice-cold 70% ethanol was added to the pellet and the tube was inverted. The sample was 
spun down at max speed for 2 minutes at 4°C and the supernatant was removed thoroughly using 
an aspirator. The pellet was air dried until the pellet looked translucent. The pellet was 
resuspended in Buffer EB. The plasmid DNA was then used for restriction enzyme digestion and 
candidate plasmids were sent for Sanger sequencing. 
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